The cleavage of target proteins by proteases is critical for many biological processes 1,2 . However, the unbridled enzymatic activity of proteases can inflict catastrophic damage. Accordingly, proteolytic activity is under strict spatial and temporal control. This control is achieved by the binding of protease-inhibitor proteins, as well as the biosynthesis and transport of proteases as inactive zymogens [3] [4] [5] [6] . These zymogens are activated upon cleavage by other proteases or in an autocatalytic manner. Similar to proteases, ribonucleases manifest an enzymatic activity that can be cytotoxic 7 . By analogy to the control of proteolytic activity by protease-inhibitor proteins, ribonucleolytic activity is controlled by ribonuclease-inhibitor proteins 8 . The resulting complexes can have K d values in the femtomolar range, indicative of an evolutionary imperative to control ribonucleolytic activity. However, no zymogens are known for ribonucleases. Here, we demonstrate that a ribonuclease can be transformed into a zymogen that unleashes its enzymatic activity only in the presence of a highly specific protease.
Plasmepsin II site Fig. 1 Design of a ribonuclease zymogen. a, Scheme for creating a zymogen in which a circular permutation creates a steric block of the active site. b, Structural model of the unactivated ribonuclease A zymogen with 88/89 termini, 14-residue linker and six disulfide bonds. The conformational energy of the non-wild type residues was minimized with the program SYBYL (Tripos). Atoms of the linker and cystines are shown explicitly, and the two non-native cystines are labeled. c, Scheme of the primary sequence of ribonuclease A zymogens. The location of α-helices (cylinders) and β-strands (arrows) are indicated. The nine new termini (black triangles), 14-residue linker (boxed) and four native and one non-native (Cys4-Cys118) cystine are indicated.
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created by circular permutation of the polypeptide chain 11 , which is a natural mechanism by which active sites migrate along a polypeptide chain 12 and new protein folds evolve 13 .
The distance between the original N and C termini of RNase A is ∼30 Å, which could be spanned by as few as eight residues. A linker connecting the original N and C termini must, however, be long enough to leave intact the structure of RNase A and to allow access by a protease but short enough to prevent the binding of substrate RNA. Our molecular modeling suggested that a linker of 14 residues would meet these criteria (Fig. 1b) .
As a protease, we chose plasmepsin II 14, 15 . This highly specific aspartyl protease is produced by Plasmodium falciparum, which is responsible for most cases of malaria. The protease catalyzes the hydrolysis of the αPhe33-Leu34 peptide bond in human hemoglobin 16, 17 . Plasmepsin II itself is biosynthesized as a zymogen that is activated in vivo by another protease 18, 19 .
The location of the new termini is crucial to the properties of a circular permutation. We selected nine sites for new termini (Fig. 1c) . Each of these sites lies between different cysteine residues, so that each permuted protein has a distinct disulfidebonding pattern. In addition, most of the new termini are in β-turns or surface loops, which are probably more tolerant of change than α-helices or β-strands. We used the most stable known variant of RNase A as a template for our zymogen. This variant, A4C/V118C RNase A, has all four native disulfide bonds plus a nonnative, fifth disulfide bond between an N-and C-terminal residue 20 .
Zymogen optimization
We produced each ribonuclease zymogen in Escherichia coli as an inclusion body and then subjected each to oxidative folding in vitro 21, 22 . Most of the nine zymogens -those with termini at residues 20/21, 67/71, 88/89, 104/105 and 113/114 -were able to fold properly. These zymogens were purified by gel filtration and cation-exchange chromatography. Treatment with plasmepsin II increased the ability of each ribonuclease zymogen to catalyze the cleavage of tetranucleotide substrate (Table 1) . Apparently, the intact linker excludes even a small substrate from the active site. The relative activity of an activated and unactivated zymogen is likely to increase with a longer RNA substrate or an RNA substrate with secondary structure. The increase in ribonucleolytic activity after addition of plasmepsin II was rapid and catalytic (Fig. 2) .
The activated zymogens have dissimilar ribonucleolytic activity ( Table 1 ), indicating that the location of the new termini can have a detrimental effect on catalysis. For example, the zymogen with 67/71 termini has a perturbation near a nucleobasebinding subsite 10 . The ribonucleolytic activity of that zymogen is low and increases by only three-fold after activation by plasmepsin II. In contrast, the zymogen with 88/89 termini gains nearly 10 3 -fold activity, and has a k cat / K m value almost equal to that of wild type RNase A. Residues 88 and 89 are remote from the active site (Fig. 1b) and have no known role in catalysis 9, 10 . Moreover, the enzymatic activity of the zymogen with 88/89 termini did not increase in the presence of a HeLa cell extract (data not shown), which contains nonspecific proteases. Thus, activation requires specific proteolysis.
All of the ribonuclease zymogens had a T m value that was greater than physiological temperature (37 °C) but lower than that of the wild type enzyme (62 °C) ( Table 1) . Activation by plasmepsin II increased the value of T m by 5-9 °C. Such an increase in conformational stability after activation is a desirable characteristic. Less stable proteins are more susceptible to nonspecific proteolytic degradation 20, 23 . Accordingly, the ribonuclease zymogens are probably degraded more quickly in the absence of their activating protease than in its presence.
The ideal zymogen should have low enzymatic activity before activation. All of the zymogens met this criterion (Table 1) , as all have k cat / K m values <2 × 10 4 M -1 s -1 . Such low activity is of no known biological consequence for a variant of RNase A. For example, G88R RNase A has k cat / K m = 1.4 × 10 7 M -1 s -1 and has wellcharacterized toxicity to human myelogenous leukemia cells 22, 24 . In contrast, K41A/G88R RNase A has k cat / K m = 6.5 × 10 3 M -1 s -1 and is not toxic to these cells 24 . Likewise, we find that the zymogen with 20/21 termini (which has k cat / K m = 1.02 × 10 4 M -1 s -1 and T m = 48°C; Table 1) is not cytotoxic at concentrations up to 25 µM.
The ideal zymogen should also have high (that is, nearly wild type) enzymatic activity after activation. The ribonuclease zymogen with 88/89 termini best met this criterion (Table 1) . Therefore, we subjected this zymogen to further modification. Decreasing the linker from 14 to 13 residues had little effect on the ribonucleolytic activity or conformational stability of the zymogen with 88/89 termini, either before or after activation (Fig. 3a) . In contrast, increasing the linker from 14 to 15 residues had the undesirable effect of increasing the ribonucleolytic activity before plasmepsin II activation. This finding validates our concern that a long linker could allow a substrate greater access to the active site. The introduction of a new disulfide bond that links the 88/89 termini increased the conformational stability of the zymogen. The T m value of the zymogen with 88/89 termini and six disulfide bonds was 50 °C before activation and 60 °C after activation (Fig. 3b) . This zymogen unfolded in a cooperative, two-state transition (Fig. 3c) , as expected for a globular protein with a single domain. Accordingly, the protein (Fig. 1b) has all of the attributes associated with known zymogens, except that its activation yields a ribonuclease.
A zymogen as a precursor
Organisms could have created zymogens to control the activity of their nonproteolytic enzymes. The near absence of natural nonprotease zymogens could indicate that creating a zymogen from an existing enzyme (Fig. 1a) is more difficult than evolving alternative mechanisms to control enzymatic activity. In addition, the unique ability of proteases to undergo autocatalytic activation could facilitate the evolution of protease zymogens but not zymogens of other enzymes.
Zymogen creation provides a versatile option for the control of enzymatic activity. This strategy avails new applications for enzymes in biotechnology and medicine; for example, a 'Trojan horse' based on a ribonuclease zymogen could have pharmacological use. RNase A can enter human cells, and that process is enhanced by the fusion of a protein transduction domain 25 . Simple variants of both RNase A 22, 26 and its human homolog 27 are toxic to cancer cells in vitro. An amphibian homolog, Onconase, is now in Phase III clinical trials for the treatment of malignant mesothelioma 7, 28 . RNase A zymogens activated by pathogenic proteases could extend the chemotherapeutic utility of ribonucleases to maladies other than cancer. Such a chemotherapeutic strategy, which relies on the function of an enzyme rather than its inhibition, could evade known mechanisms of microbial resistance.
Methods
Instrumentation. UV absorbance measurements were made on a Cary Model 3 or 50 spectrophotometer (Varian) equipped with a Cary temperature controller. Fluorescence measurements were made on a QuantaMaster1 photon-counting fluorometer (Photon Technology International) equipped with sample stirring.
Molecular modeling. The atomic coordinates of wild type RNase
A were obtained from the Protein Data Bank (accession code 7RSA) 29 . A model of the structure of each RNase A zymogen was created by using SYBYL (Tripos) on an Octane computer (Silicon Graphics). The program was used to link the N and C termini by a bridge of 13-15 residues, replace residues (for example, A4C and V118C), break the polypeptide chain in one of nine places and minimize the conformational energy of the new residues in the resulting structures.
Preparation of zymogens.
A scheme showing the construction of a plasmid pET22b+/19N, which directs the expression of an RNase A zymogen, is shown in Fig. 4 . Plasmid pET22b+/AGV, which directs the expression of A4C/G88R/V118C RNase A 20 , served as the starting material. Therefore, all of the RNase A zymogens (except those with termini at residues 88/89) had an Arg 88. The G88R mutant of RNase A is able to manifest its ribonucleolytic activity in the presence of the cytosolic ribonuclease inhibitor protein 20, 22, 26 .
The MscI site in plasmid pET22b+/AGV was replaced with a BstZI site (underlined) by single-stranded DNA mutagenesis using the oligonucleotide 5′-CACAAGTTTCCTTGCCGGCCGCCGGCTGGGCAGC-GAG-3′, resulting in plasmid p1453. The SalI site was removed by using the oligonucleotide 5′-CCGCAAGCTTGCGAGGATCCCACTGAA-GCATCAAA-3′, resulting in plasmid p152G. Plasmid p1453 was subjected to digestion with BstZI and SalI endonucleases, and a 385 base pair (bp) fragment was purified after electrophoresis in an agarose gel. Plasmid p152G was subjected to restriction enzyme digestion with BstZI and XhoI endonucleases, and a 5,805 bp fragment was purified. The two DNA fragments were ligated (XhoI and SalI digestion yield compatible cohesive ends), resulting in plasmid pSMFII. Plasmid pSMFII was then subjected to digestion with the BamHI and BstZI endonucleases, and a 6,190 bp fragment was purified. A phosphorylated double-stranded oligonucleotide encoding a plasmepsin II cleavage sequence within 13, 14 or 15 amino acids and having BstZI (italics)-and BamHI (bold)-compatible cohesive ends was ligated to the pSMFII/BstZI/BamHI fragment (5′-GATC-TAAACCGATTGAATTTCTGGAACTGAA-3′ and 5′-GGCCTTCAGTTCCA-GAAATTCAATCGGTTTA-3′ for the 13-residue linker, 5′-GATCTGG CAAACCGATTGAATTTCTGGAACTGAA-3′ and 5′-GGCCTTCAGTTCCA GAAATTCAATCGGTTTGCCA-3′ for the 14-residue linker, and 5′-GA Number of residues in loop TCTGGCAAACCGATTGAATTTCTGGAACTGGGCAA-3′ and 5′-GGC-CTTGCCCAGTTCCAGAAATTCAATCGGTTTGCCA-3′ for the 15-residue linker). Oligonucleotide primers corresponding to different new N termini were engineered to have an NdeI-compatible cohesive end, and those corresponding to different new C termini were engineered to have a SalI-compatible cohesive end. These pairs of primers were used in the PCR, and the resulting products were purified and subjected to digestion with the NdeI and SalI endonucleases. The resulting fragments were inserted into the NdeI and SalI sites of plasmid pET22b+ to produce plasmid pET22b+/19N (Fig. 4) . The Cys4-Cys118 cystine was removed from the circularly permuted RNase A with 88/89 termini by PCR-based site-directed mutagenesis using oligonucleotides 5′-AAGGAAACTGCAGCAGCCAAG TTTGAGCGGCAGC-3′ and 5′-GCTGCCGCTCAAACTTGGCTGCTGCAG TTTCCTT-3′ for the C4A substitution and 5′-GCATCAAAGTGGACTG-GCACGTACGGGTTTCCC-3′ and 5′-GGGAAACCCGTACGTGCCAGTC-CACTTTGATGC 3′ for the C118V substitution. Digestion with PstI endonuclease (bold) was used to screen for the C4A substitution, and digestion with BsiWI endonuclease (italics) was used to screen for the C118V substitution.
The permuted RNase A with 88/89 termini and a sixth disulfide bond was created by PCR of plasmid pSMFII using oligonucleotide primers 5′-CGTGAGCATATGTGTTCCAAGTACCCC-3′ and 5′-GTTGG-GGTCGACCTACTAGCACGTCTCACGGCAGTC-3′ with the NdeI (bold) and SalI (italics) restriction sites. The PCR product was purified, digested with the NdeI and SalI endonucleases, and inserted into the NdeI and SalI sites of plasmid pET22b+. The resulting plasmid encodes a permuted variant with the eight native cysteine residues plus Cys4, Cys88, Cys89 and Cys118.
Oligonucleotides were annealed by dissolving them to 0.25 mM in 10 mM Tris-HCl buffer, pH 8.0, containing 50 mM NaCl and 1 mM EDTA. The resulting solution was heated to 95°C in a water bath and cooled slowly (over ≥4 h) to room temperature. The resulting double-stranded oligonucleotides were subjected to 5′ phosphorylation by treatment for 1 h with T4 polynucleotide kinase.
The production, folding and purification of RNase A zymogens were done as described for other variants of RNase A 21, 22 , except that the oxidative folding was done at pH 7.8 for at least 48 h.
Preparation of protease. The production, folding and purification of proplasmepsin II were done as described 30, 31 . Proplasmepsin II was activated by the addition of 1 µl of 1.0 M sodium citrate buffer, pH 4.7, to 9 µl of a solution of proplasmepsin II (10 µM in 20 mM Tris-HCl buffer, pH 8.0) and incubation of the resulting solution at 37 °C for 45 min.
Activation of zymogens.
RNase A zymogens were activated by mixing 19.5 µl of a solution of 25 µM zymogen with 0.5 µl of a solution of 10 µM activated plasmepsin II and then incubating the resulting mixture at 37°C for 15 min. Activation was stopped by the addition of pepstatin A to a final concentration of 1 µM. To assess zymogen activation, reaction mixtures were subjected to electrophoresis in a 15% (w/v) polyacrylamide gel containing 1% (w/v) SDS and assayed for ribonucleolytic activity as described 32 .
Enzymatic activity of zymogens. The ribonucleolytic activity of RNase A zymogens was evaluated before and after activation with an assay using 6-FAM-dArU(dA) 2 -6-TAMRA (Integrated DNA Technologies), where 6-FAM is 6-carboxyfluorescein and 6-TAMRA is 6-carboxytetramethylrhodamine 32 . Cleavage of this fluorogenic substrate results in a ∼200-fold increase in fluorescence intensity (excitation at 492 nm and emission at 515 nm). Assays were performed at 23 °C in 2.0 ml of 0.10 M MES-NaOH buffer, pH 6.0, containing 0.10 M NaCl, 50 nM 6-FAM-dArU(dA) 2 -6-TAMRA and 0.1 nM-1 µM zymogen. Data were fit to the equation k cat / K m = (∆I / ∆t) / ((I f -I 0 )[E]), where ∆I / ∆t is the initial velocity of the reaction, I 0 is the fluorescence intensity before the addition of enzyme, I f is the fluorescence intensity after complete hydrolysis with excess wild type enzyme and [E] is the ribonuclease concentration.
Cytotoxicity of zymogens.
The toxicity of the unactivated zymogen with 20/21 termini for K-562 cells, which derive from a continuous human chronic myelogenous leukemia line, was assayed as described 22 .
Conformational stability of zymogens. The conformational stability of RNase A zymogens was assessed before and after activation by recording the change in absorbance at 287 nm with increasing temperature 33 . The temperature of a solution of 0.15-0.25 mg ml -1 RNase A zymogen in PBS was increased continuously from 20 to 70°C at 0.15°C min -1 . The absorbance was recorded at 1 °C intervals and fit to a two-state model for denaturation. The temperature at the midpoint of the transition is defined as T m .
